Day: June 22, 2024

Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions

Written by Customer Service on . Posted in Public Companies.

Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and cardiovascular disease risk GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), on cardioinflammatory lipids at the American Diabetes Association’s (ADA) 84th Scientific Sessions. “Dyslipidemia is one of the most significant co-morbidities of obesity, impacting up to 70% of patients with obesity,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “These data add to the differentiated profile of pemvidutide and reinforce...

Continue reading

Casino Group: Agreement with Rocca and Auchan Retail France for the sale of Codim 2

Written by Customer Service on . Posted in Public Companies.

Casino Group has signed an agreement with Rocca and Auchan Retail France for the sale of its subsidiary Codim 2 Paris, 22 June 2024 Casino Group announces today that it has signed a unilateral purchase agreement for the sale of Codim 2, which operates 4 hypermarkets, 9 supermarkets, 3 cash & carries and 2 drive-throughs in Corsica, with sales of 332 million euros excluding taxes in 2023. As part of the sale, Rocca Group has undertaken to take over all the stores, which will be operated under the Auchan banner, as well as all Codim 2 store and head office employees. Completion of the sale is expected to take place after consultation with employee representative bodies and subject to clearance by the competent competition authorities.          *** This press release has been prepared for information purposes only and should not be construed...

Continue reading

INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions

Written by Customer Service on . Posted in Public Companies.

Afrezza® Afrezza® (insulin human) Inhalation Powder. Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17% with usual care and 24% had time-in-range (TIR) above 70% with no increased hypoglycemia compared with 13% with usual care More than 50% of subjects at the end of the study expressed an interest in continuing to use Afrezza® DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 22, 2024 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung...

Continue reading

Mountain Assets Discusses New SDA Project in Bundaberg with a Local Radio Station

Written by Customer Service on . Posted in Mergers And Acquisitions.

BUNDABERG, Australia, June 21, 2024 (GLOBE NEWSWIRE) — Following the announcement of a new Specialist Disability Accommodation (SDA) project in Bundaberg, Mountain Assets engaged with the local media to provide more details about this significant development. Al Wheldon and Adam Newman from Mountain Assets, participated in an interview with Hitz939, sharing insights into the $6.4 million development aimed at enhancing the quality of life for individuals with high physical support needs. Interview Highlights: Project Overview Mountain Assets and Sumo Managed Funds are collaborating on a futuristic project in Bundaberg’s Kalkie area. The development includes the construction of five state-of-the-art homes specifically designed for NDIS participants with high physical support needs. Each home will feature three bedrooms and three...

Continue reading

B2Gold Announces Voting Results from its 2024 Annual General and Special Meeting

Written by Customer Service on . Posted in Public Companies.

VANCOUVER, British Columbia, June 21, 2024 (GLOBE NEWSWIRE) — B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on Thursday, June 20, 2024. A total of 845,972,994 common shares were voted at the Meeting, representing 64.75% of the votes attached to all outstanding common shares. Shareholders voted overwhelmingly in favour of all items of business before the Meeting. The eight director nominees listed in B2Gold’s Management Information Circular (the “Circular”) dated May 8, 2024, were elected as directors of B2Gold to hold office for the ensuing year or until their successors are elected or appointed. Detailed results of the vote for each director are set out below: Name Total...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.